PharmGKB contains no dosing guidelines for this gene. To report known dosing guidelines, or if you are interested in developing guidelines,
click here.
PharmGKB contains no drug labels with pharmacogenomic information for this gene. To report a drug label with PGx,
click here.
PharmGKB contains no clinical annotations for this gene. To report clinical variants,
click here.
PharmGKB contains no genetic tests for this gene. To report genetic tests,
click here.
The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the
"Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the
corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated
information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications
can be found on the Variant Page.
The tags in the first column of the table indicate what type of information can be found on the corresponding
Variant Page.
Links in the "Drugs" column lead to PharmGKB Drug Pages.
The following icons indicate that data of a certain type is available:
-
DG
Dosing Guideline information is available
-
DL
Drug Label information is available
-
CA
High-level Clinical Annotation is available
-
VA
Variant Annotation is available
-
VIP
VIP information is available
-
PW
Pathway is available
[ close ]
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP build 132
Overview
|
Alternate Names:
|
Cytochrome P-450 reductase; NADPH--cytochrome P450 reductase; NADPH-dependent cytochrome P450 reductase; OTTHUMP00000160964; OTTHUMP00000185560; OTTHUMP00000210071; cytochrome P450 reductase |
|
Alternate Symbols:
|
CPR; CYPOR; DKFZp686G04235; FLJ26468; P450R; POR |
| PharmGKB Accession Id: |
PA33532 |
Details
| Cytogenetic Location: |
chr7 :
q11.23
- q11.23
|
| GP mRNA Boundary†: |
chr7 : 75544420 - 75616173
|
| GP Gene Boundary†: |
chr7 : 75534420 - 75619173
|
| Strand: |
plus |
| Product Name: |
No data available |
†
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped
onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries
by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for
potential regulatory regions.
Publications related to POR: 17
The following icons indicate that data of a certain type is available:
-
DG
Dosing Guideline information is available
-
DL
Drug Label information is available
-
CA
High-level Clinical Annotation is available
-
VA
Variant Annotation is available
-
VIP
VIP information is available
-
PW
Pathway is available
[ close ]
|
|
Pharmacogenetics of glucocorticoid replacement could optimize the treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clinics (São Paulo, Brazil). 2011. Moreira Ricardo P P, et al. [Article:21915484@PubMed] |
|
|
The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients. Pharmacogenomics. 2011. de Jonge Hylke, et al. [Article:21770725@PubMed] |
|
|
Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. [Article:21048526@PubMed] |
|
|
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro. Pharmacogenetics and genomics. 2010. Sandee Duanpen, et al. [Article:20940534@PubMed] |
|
|
Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase. Pharmacogenetics and genomics. 2010. Agrawal Vishal, et al. [Article:20697309@PubMed] |
|
|
Genetic variation in human P450 oxidoreductase. Molecular and cellular endocrinology. 2009. Miller Walter L, et al. [Article:18930113@PubMed] |
|
|
Platinum pathway. Pharmacogenetics and genomics. 2009. Marsh Sharon, et al. [Article:19525887@PubMed] |
|
|
The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenetics and genomics. 2009. Oneda Beatrice, et al. [Article:19801957@PubMed] |
|
|
Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics. 2009. Gomes Ana M, et al. [Article:19374516@PubMed] |
|
|
Submicroscopic deletion in patients with Williams-Beuren syndrome influences expression levels of the nonhemizygous flanking genes. American journal of human genetics. 2006. Merla Giuseppe, et al. [Article:16826523@PubMed] |
|
|
Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Molecular pharmacology. 2002. Maglich Jodi M, et al. [Article:12181440@PubMed] |
|
|
Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity. Molecular pharmacology. 2000. Niitsu N, et al. [Article:10860924@PubMed] |
|
|
Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Molecular pharmacology. 1997. Schmiedlin-Ren P, et al. [Article:9145912@PubMed] |
|
|
Role of the semi-quinone free radical of the anti-tumour agent etoposide (VP-16-213) in the inactivation of single- and double-stranded phi X174 DNA. British journal of cancer. 1990. Mans D R, et al. [Article:2167725@PubMed] |
|
|
Effects of the ortho-quinone and catechol of the antitumor drug VP-16-213 on the biological activity of single-stranded and double-stranded phi X174 DNA. Biochemical pharmacology. 1988. van Maanen J M, et al. [Article:2972290@PubMed] |
|
|
Semi-quinone formation from the catechol and ortho-quinone metabolites of the antitumor agent VP-16-213. Free radical research communications. 1988. van Maanen J M, et al. [Article:2854106@PubMed] |
|
|
Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213). Cancer research. 1987. van Maanen J M, et al. [Article:3621161@PubMed] |
